Morgenstern DA, Baruchel S, Irwin MS. Current and future strategies for relapsed neuroblastoma: challenges on the road to precision therapy. J Pediatr Hematol Oncol. 2013;35:337–47.

Article  CAS  PubMed  Google Scholar 

Pandian V, Ramraj S, Khan FH, Azim T, Aravindan N. Metastatic neuroblastoma cancer stem cells exhibit flexible plasticity and adaptive stemness signaling. Stem Cell Res Ther. 2015;6:2.

Article  PubMed  PubMed Central  Google Scholar 

Khan FH, Pandian V, Ramraj SK, Aravindan S, Natarajan M, Azadi S, et al. RD3 loss dictates high-risk aggressive neuroblastoma and poor clinical outcomes. Oncotarget. 2015;6:36522–34.

Article  PubMed  PubMed Central  Google Scholar 

Somasundaram DB, Aravindan S, Gupta N, Yu Z, Baker A, Aravindan N. ALK expression, prognostic significance, and its association with MYCN expression in MYCN nonamplified neuroblastoma. World J Pediatr. 2022;18:285–93.

Article  CAS  PubMed  Google Scholar 

Loi M, Becherini P, Emionite L, Giacomini A, Cossu I, Destefanis E, et al. sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumor resistance in combination with Bortezomib. J Control Release. 2014;192:157–66.

Article  CAS  PubMed  Google Scholar 

Gasparini C, VecchiBrumatti L, Monasta L, Zauli G. TRAIL-based therapeutic approaches for the treatment of pediatric malignancies. Curr Med Chem. 2013;20:2254–71.

Article  CAS  PubMed  Google Scholar 

El-Soussi S, Hanna R, Semaan H, Khater AR, Abdallah J, Abou-Kheir W, et al. A novel therapeutic mechanism of imipridones ONC201/ONC206 in MYCN-amplified neuroblastoma cells via differential expression of tumorigenic proteins. Front Pediatr. 2021;9:693145.

Article  PubMed  PubMed Central  Google Scholar 

Huang C, He Y, Sun J, Yuan Q, Li S, Hou H, et al. Sensitizing TRAIL response via differential modulation of anti- and pro-apoptotic factors by AZD5582 combined with ER nanosomal TRAIL in neuroblastoma. Acta Histochem. 2022;124:151856.

Article  CAS  PubMed  Google Scholar 

Nieddu V, Piredda R, Bexell D, Barton J, Anderson J, Sebire N, et al. Engineered human mesenchymal stem cells for neuroblastoma therapeutics. Oncol Rep. 2019;42:35–42.

CAS  PubMed  PubMed Central  Google Scholar 

Aravindan N, Somasundaram DB, Herman TS, Aravindan S. Significance of hematopoietic surface antigen CD34 in neuroblastoma prognosis and the genetic landscape of CD34-expressing neuroblastoma CSCs. Cell Biol Toxicol. 2021;37:461–78.

Article  CAS  PubMed  Google Scholar 

Eggenhofer E, Luk F, Dahlke MH, Hoogduijn MJ. The life and fate of mesenchymal stem cells. Front Immunol. 2014;5:148.

Article  PubMed  PubMed Central  Google Scholar 

Jain D, Somasundaram DB, Aravindan S, Yu Z, Baker A, Esmaeili A, et al. Prognostic significance of NT5E/CD73 in neuroblastoma and its function in CSC stemness maintenance. Cell Biol Toxicol. 2021;39:967–89.

Article  PubMed  Google Scholar 

Smyth MJ, Cretney E, Takeda K, Wiltrout RH, Sedger LM, Kayagaki N, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon gamma-dependent natural killer cell protection from tumor metastasis. J Exp Med. 2001;193:661–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol. 2002;168:1356–61.

Article  CAS  PubMed  Google Scholar 

Rossini A, Giussani M, Giacomini A, Guarnotta C, Tagliabue E, Balsari A. Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34(+) cells in a xenograft model. Breast Cancer Res Treat. 2012;136:457–67.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Norian LA, Kresowik TP, Rosevear HM, James BR, Rosean TR, Lightfoot AJ, et al. Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapy. PLoS ONE. 2012;7:e31085.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liu Z, Li S, Ma T, Zeng J, Zhou X, Li H, et al. Secreted TRAIL gene-modified adipose-derived stem cells exhibited potent tumor-suppressive effect in hepatocellular carcinoma cells. Immun Inflamm Dis. 2021;9:144–56.

Article  CAS  PubMed  Google Scholar 

Jyotsana N, Zhang Z, Himmel LE, Yu F, King MR. Minimal dosing of leukocyte targeting TRAIL decreases triple-negative breast cancer metastasis following tumor resection. Sci Adv. 2019;5:eaaw4197.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zhu W, Zhang H, Shi Y, Song M, Zhu B, Wei L. Oncolytic adenovirus encoding tumor necrosis factor-related apoptosis inducing ligand (TRAIL) inhibits the growth and metastasis of triple-negative breast cancer. Cancer Biol Ther. 2013;14:1016–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chulpanova DS, Pukhalskaia TV, Gilazieva ZE, Filina YV, Mansurova MN, Rizvanov AA, et al. Cytochalasin B-induced membrane vesicles from TRAIL-overexpressing mesenchymal stem cells induce extrinsic pathway of apoptosis in breast cancer mouse model. Curr Issues Mol Biol. 2023;45:571–92.

Article  CAS  PubMed  PubMed Central  Google Scholar